More Articles

Modify Fc fucosylation and β-galactosylation for biobetter MAbs Biosimilars/Research | Posted 28/01/2010

In an article by Dr Claire Morgan and Dr Daryl Fernandes of Ludger, published in IPI of Autumn 2009, it is shown how both the original drug manufacturers and the designers of follow-on biologics co...

Design out NeuGc, Fab glycosylation for biobetter MAbs Biosimilars/Research | Posted 28/01/2010

In an article by Dr Claire Morgan and Dr Daryl Fernandes of Ludger, published in IPI of Autumn 2009, it is shown how both the original drug manufacturers and the designers of follow-on biologics co...

Design out Gal-α(1,3)-Gal for biobetter MAbs Biosimilars/Research | Posted 28/01/2010

In an article by Dr Claire Morgan and Dr Daryl Fernandes of Ludger, published in IPI of Autumn 2009, it is shown how both the original drug manufacturers and the designers of follow-on biologics co...

Strategy and tools for building glycoengineered biobetter MAbs Biosimilars/Research | Posted 28/01/2010

In an article by Dr Claire Morgan and Dr Daryl Fernandes of Ludger, published in IPI of Autumn 2009, it is shown how both the original drug manufacturers and the designers of follow-on biologics co...

When is a glycoengineered biobetter commercially better than a biosimilar? Biosimilars/Research | Posted 28/01/2010

In an article by Dr Claire Morgan and Dr Daryl Fernandes of Ludger, published in IPI of Autumn 2009, it is shown how both the original drug manufacturers and the designers of follow-on biologics co...

Ludger’s GTO-QbD: Defining glycovariant biobetter MAbs Biosimilars/Research | Posted 28/01/2010

One area of great interest to developers, copiers and improvers of therapeutic antibodies is glycosylation, since it can significantly influence the safety and efficacy profiles of the drug. In an...

12 years exclusivity workable for patients; not anticompetitive Biosimilars/General | Posted 26/01/2010

On IPWatchdog.com Gene Quinn distinguishes facts from fiction about biosimilars.

Data exclusivity is not the same as market exclusivity Policies & Legislation | Posted 26/01/2010

Gene Quinn distinguishes facts from fiction on biosimilars on IPWatchdog.com.According to him, data exclusivity is not the same as market exclusivity. “During a period of data exclusivity, a compet...